Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAIL L WRIGHT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1669432290
CMS profile
211190
Location
HUDSON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,378.19

160 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,079.09 157
Long term medical supply or device loan $299.10 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $524.24 17
Janssen Biotech, Inc. $286.70 13
Seagen Inc. $202.45 15
Organon LLC $178.31 2
AstraZeneca Pharmaceuticals LP $158.58 8
E.R. Squibb & Sons, L.L.C. $129.24 7
Incyte Corporation $124.45 6
Daiichi Sankyo Inc. $101.58 5
Exelixis Inc. $100.18 5
Pharmacyclics LLC, An AbbVie Company $99.66 4
Merck Sharp & Dohme LLC $94.95 5
Gilead Sciences, Inc. $92.41 5
Bayer Healthcare Pharmaceuticals Inc. $91.03 5
GENZYME CORPORATION $89.27 4
Genentech USA, Inc. $86.89 5
Mirati Therapeutics, Inc. $84.89 4
GlaxoSmithKline, LLC. $80.39 4
PFIZER INC. $80.13 4
TerSera Therapeutics LLC $65.08 2
Celgene Corporation $61.75 3
Eisai Inc. $48.78 2
BeiGene USA, Inc. $42.10 2
ARRAY BIOPHARMA INC $41.64 3
Regeneron Healthcare Solutions, Inc. $41.25 2
Takeda Pharmaceuticals U.S.A., Inc. $39.15 2
Apellis Pharmaceuticals, Inc. $36.27 2
MorphoSys, US Inc. $32.00 2
SOBI, INC $31.68 2
G1 Therapeutics, Inc. $30.58 2
Blueprint Medicines Corporation $28.68 2
Lilly USA, LLC $27.80 1
AbbVie Inc. $25.48 1
Foundation Medicine, Inc. $22.41 1
ImmunoGen, Inc. $22.36 1
Puma Biotechnology, Inc. $18.80 1
Stemline Therapeutics Inc. $18.02 1
ADC Therapeutics America, Inc. $16.22 1
CTI BioPharma Corp. $16.12 1
EMD Serono, Inc. $14.66 1
TAIHO ONCOLOGY, INC. $14.60 1
Dendreon Pharmaceuticals LLC $14.49 1
Janssen Pharmaceuticals, Inc $13.55 1
Astellas Pharma US Inc $13.14 1
Kyowa Kirin, Inc. $13.12 1
Pharmacosmos Therapeutics Inc. $12.91 1
Rigel Pharmaceuticals, Inc. $10.20 1

Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAIL L WRIGHT

NPI 1669432290 · CMS profile ID 211190

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HUDSON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669432290?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669432290?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669432290?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 160 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669432290?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

160 matching records · $3,378.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 160 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 160.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $16.2205/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049215753 CMS
Blueprint Medicines Corporation $13.6904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051260721 CMS
Pharmacyclics LLC, An AbbVie Company $25.3704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297985 CMS
BeiGene USA, Inc. $18.6804/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193433 CMS
Novartis Pharmaceuticals Corporation $15.7804/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258461 CMS
Kyowa Kirin, Inc. $13.1204/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026995589 CMS
AstraZeneca Pharmaceuticals LP $14.7904/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011494841 CMS
Janssen Biotech, Inc. $15.1804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988245947 CMS
Genentech USA, Inc. $18.7704/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040366349 CMS
Novartis Pharmaceuticals Corporation $10.0304/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258475 CMS
E.R. Squibb & Sons, L.L.C. $18.6904/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015541971 CMS
Novartis Pharmaceuticals Corporation $20.5504/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258481 CMS
Daiichi Sankyo Inc. $18.2504/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006352529 CMS
Stemline Therapeutics Inc. $18.0204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040026249 CMS
Janssen Biotech, Inc. $26.8704/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988245899 CMS
Janssen Biotech, Inc. $26.8704/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988245923 CMS
Apellis Pharmaceuticals, Inc. $16.8604/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056349165 CMS
SOBI, INC $16.4004/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038075063 CMS
Novartis Pharmaceuticals Corporation $14.8403/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258479 CMS
Pharmacyclics LLC, An AbbVie Company $22.5803/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297983 CMS
E.R. Squibb & Sons, L.L.C. $17.5603/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015541967 CMS
Novartis Pharmaceuticals Corporation $18.3403/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258477 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.7903/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000689915 CMS
Mirati Therapeutics, Inc. $24.6903/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006565 CMS
Seagen Inc. $12.3203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995792219 CMS
ARRAY BIOPHARMA INC $15.7603/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049419959 CMS
Seagen Inc. $13.5403/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995792237 CMS
Foundation Medicine, Inc. $22.4103/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058786377 CMS
MorphoSys, US Inc. $13.9803/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060327653 CMS
Dendreon Pharmaceuticals LLC $14.4903/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060292565 CMS
Daiichi Sankyo Inc. $13.4103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006330355 CMS
Exelixis Inc. $21.0803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044528655 CMS
Exelixis Inc. $18.8103/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044527687 CMS
E.R. Squibb & Sons, L.L.C. $19.7003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015541911 CMS
Novartis Pharmaceuticals Corporation $19.5802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258473 CMS
AbbVie Inc. $25.4802/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999716401 CMS
Janssen Biotech, Inc. $26.8702/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988245867 CMS
Janssen Pharmaceuticals, Inc $13.5502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987877261 CMS
Apellis Pharmaceuticals, Inc. $19.4102/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056360511 CMS
Pharmacyclics LLC, An AbbVie Company $24.4602/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297981 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $99.7002/15/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424403 CMS
Novartis Pharmaceuticals Corporation $11.8102/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258471 CMS
Novartis Pharmaceuticals Corporation $21.9402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993258469 CMS
GENZYME CORPORATION $18.2002/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049859829 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.6602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055674487 CMS
BeiGene USA, Inc. $23.4201/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193431 CMS
AstraZeneca Pharmaceuticals LP $14.9701/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011302515 CMS
Janssen Biotech, Inc. $19.3201/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988245911 CMS
Organon LLC $161.5901/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046926631 CMS
Organon LLC $16.7201/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046926643 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,001.62 142
PY2020 $1,234.24 77
PY2021 $1,869.22 118
PY2022 $2,856.92 161
PY2023 $3,378.19 160
PY2024 $7,126.96 199
PY2025 $2,767.14 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,228,719.16 48
PY2024 Principal investigator $364,881.43 85
PY2023 Principal investigator $1,584,275.57 174
PY2022 Principal investigator $2,421,068.49 240
PY2021 Principal investigator $3,323,416.04 215
PY2020 Principal investigator $3,469,029.84 182
PY2019 Principal investigator $1,375,448.56 108

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,250.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746863
Principal investigator 1 PFIZER INC. $631.80 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228724558
Principal investigator 1 Daiichi Sankyo Inc. $650.00 11/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378089
Principal investigator 1 Daiichi Sankyo Inc. $690.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378083
Principal investigator 1 Daiichi Sankyo Inc. $125.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378085
Principal investigator 1 Daiichi Sankyo Inc. $1,623.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378091
Principal investigator 1 Daiichi Sankyo Inc. $2,230.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378087
Principal investigator 1 PFIZER INC. $5,891.00 10/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228740893
Principal investigator 1 PFIZER INC. $775.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228756483
Principal investigator 1 PFIZER INC. $2,145.60 09/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228762040
Principal investigator 1 Daiichi Sankyo Inc. $5,278.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378077
Principal investigator 1 Daiichi Sankyo Inc. $650.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378079
Principal investigator 1 Daiichi Sankyo Inc. $5,733.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378081
Principal investigator 1 Genmab U.S., Inc. $51,505.07 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235934170
Principal investigator 1 PFIZER INC. $3,490.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228767723
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228765086
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228784024
Principal investigator 1 PFIZER INC. $1,000.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228773837
Principal investigator 1 Eli Lilly and Company $1,982.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187887832
Principal investigator 1 Daiichi Sankyo Inc. $4,004.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378065
Principal investigator 1 Daiichi Sankyo Inc. $5,915.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378067
Principal investigator 1 Daiichi Sankyo Inc. $650.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378069
Principal investigator 1 Daiichi Sankyo Inc. $4,459.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378071
Principal investigator 1 Daiichi Sankyo Inc. $362.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378073
Principal investigator 1 Daiichi Sankyo Inc. $4,823.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378075
Principal investigator 1 GlaxoSmithKline, LLC. $334.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE-ATLANTA-UNITE
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1192171605
Principal investigator 1 PFIZER INC. $775.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228794016
Principal investigator 1 PFIZER INC. $1,250.00 06/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228793043
Principal investigator 1 AstraZeneca Pharmaceuticals LP $291,340.36 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551038
Principal investigator 1 GlaxoSmithKline, LLC. $1,479.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE-ATLANTA-UNITE
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1192171608
Principal investigator 1 PFIZER INC. $1,250.00 05/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228771534
Principal investigator 1 PFIZER INC. $5,327.80 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228772789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $395,803.93 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551042
Principal investigator 1 PFIZER INC. $775.00 04/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228796294
Principal investigator 1 PFIZER INC. $500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228780585
Principal investigator 1 Eli Lilly and Company $8.40 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187882398
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,200.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in No dispute reported 06/30/2026 1190304453
Principal investigator 1 PFIZER INC. $9,197.80 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228788813
Principal investigator 1 PFIZER INC. $1,000.00 03/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228767003
Principal investigator 1 PFIZER INC. $1,250.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228765566
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,354.71 02/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY No dispute reported 06/30/2026 1185551040
Principal investigator 1 PFIZER INC. $1,250.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228797553
Principal investigator 1 PFIZER INC. $4,457.10 02/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228749759
Principal investigator 1 Novartis Pharmaceuticals Corporation $139,086.39 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303223
Principal investigator 1 PFIZER INC. $1,500.00 01/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228724212
Principal investigator 1 PFIZER INC. $11,483.80 01/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228799031
Principal investigator 1 PFIZER INC. $1,250.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228723926
Principal investigator 1 AstraZeneca Pharmaceuticals LP $246,483.40 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551036